David Marks, MBBS, PhD, FRACP, FRCPath, is a Professor of Hematology, Director of the Bristol BMT Unit and Head of the ALL program at the University Hospitals Bristol NHS Foundation Trust in Bristol, UK.
Prof. Marks received his medical degree from the University of Melbourne in Melbourne Australia, followed by his clinical training which he completed largely at the Royal Melbourne Hospital, in Melbourne, Australia. He was awarded his FRACP in 1988 from The Royal Australasian College of Physicians and his PhD from the University of Melbourne in 1990. Prof. Marks then moved to London in the UK to receive further training in stem cell transplantation at the Hammersmith Hospital, followed by three years at Hahnemann University in Philadelphia, PN, as an Assistant Professor in Hematological Oncology.
Prof. Marks currently serves as the Transplant coordinator and Deputy Chair of the NCRI ALL working group and from 2007-2009 he was President of the BSBMT. He currently chairs the Adjudication Committee of BSBMT and was previously the Vice Chair (Europe) of the Advisory Committee of the CIBMTR and the Scientific Secretary for EBMT London 2013.
Speaking on stem cell transplantation for ALL
Prof. Marks’ research is focused on clinical aspects of stem cell transplantation, in particular the use of alternative donors, for acute lymphoblastic leukemia (ALL) and infection.
Prof. Marks was the Chief Investigator of a large multinational study investigating the treatment of antifungal prophylaxis following allogenic hematopoietic stem-cell transplantation.